AbbVie (ABBV) Stock Analysis & AI Equity Report

Drug Manufacturers - General USD Explore free reports

AbbVie (ABBV) overview

AbbVie (ABBV) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 61,160m and operating profit of USD 15,075m; the year-end share price was 228.49 USD and market capitalisation was USD 403,942m. AbbVie is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get AbbVie's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD -3,270mFY 2025
Share price228.49 USDFY 2025 year end
RevenueUSD 61,160mFY 2025
Operating profitUSD 15,075mFY 2025
Net earningsUSD 4,226mFY 2025
Market capitalisationUSD 403,942mFY 2025 year end

About AbbVie

AbbVie is a research-based biopharmaceutical company that discovers, develops, manufactures, markets, and sells medicines and therapies. Its portfolio spans immunology, neuroscience, oncology, and aesthetics, with products addressing autoimmune and other serious diseases. Examples include Skyrizi, a biologic therapy for several autoimmune conditions, and Rinvoq, an oral medicine for inflammatory diseases. The company organizes commercial activities by region or therapeutic area.

Generate the AbbVie report

AbbVie is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for AbbVie and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on AbbVie

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.